Nitroimidazole antimycobacterial (MDR-TB)

Delamanid

Brand names: Deltyba

Delamanid is an antimycobacterial agent used as part of an appropriate combination regimen for multidrug-resistant pulmonary tuberculosis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits the synthesis of mycolic acids, key components of the mycobacterial cell wall, thereby impairing the integrity of Mycobacterium tuberculosis.

Prescribing in practice

Delamanid prolongs the QT interval, so obtain a baseline electrocardiogram and correct electrolyte abnormalities, with caution when combined with other QT-prolonging drugs.
It must only be used within a combination regimen designed by a specialist to prevent emergence of further resistance.
Hypoalbuminaemia increases the risk of QT prolongation and warrants particular caution.

Monitoring

Monitor the electrocardiogram and serum electrolytes, including potassium, periodically throughout treatment.

Counselling the patient

Take every dose as prescribed and with food, and do not stop the regimen early as this risks treatment failure and resistance.
Report palpitations, fainting, or dizziness, which may indicate a heart-rhythm effect.

Evidence & guidelines

Use in multidrug-resistant tuberculosis is supported by WHO recommendations and the controlled trials that informed its regulatory approval.

Reference: WHO MDR-TB; BTS/SIGN; UKHSA; SmPC; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Pathways